[Skip to Content]
[Skip to Content Landing]
December 21, 1984

Ranitidine and Cimetidine-Reply

Author Affiliations

Scripps Clinic Medical Group, Inc La Jolla, Calif

JAMA. 1984;252(23):3253. doi:10.1001/jama.1984.03350230014018

In Reply.—  The comments of Humphries and associates are appreciated and offer an opportunity for further discussion of H2-receptor antagonists. The purpose of the ranitidine article was to familiarize clinicians with this new drug, to compare it with its predecessor, cimetidine, and to indicate areas where a choice between the two might offer benefits to patients, within the constraints of a BRIEF REPORT. I think these objectives were achieved.Regarding several of the stated concerns, brief responses should suffice. (1) The pharmacokinetic data presented are representative of the pharmacologic behavior of ranitidine, clearly state the doses used in the studies cited, and offer a comparison of the effects of ranitidine and cimetidine on inhibition of gastric acid secretion, the latter being a feature used by others for similar illustration.1 An extensive literature is available for Humphries et al and other interested readers desiring more detailed information.2